Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orexigen Therapeutics Inc. OREXQ

Healthcare Drug Manufacturers - Major
"Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity."

Recent & Breaking News (OTCPK:OREXQ)

Orexigen Therapeutics to Speak at the Wells Fargo Securities 2015 Healthcare Conference

PR Newswire September 4, 2015

Orexigen Therapeutics Reports Financial and Business Results for the Second Quarter Ended June 30, 2015

PR Newswire August 6, 2015

Orexigen Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical Company

PR Newswire August 6, 2015

Orexigen and Takeda Announce an Amended and Restated Collaboration Agreement

PR Newswire August 6, 2015

Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2015 Financial Results on August 6, 2015

PR Newswire July 24, 2015

Orexigen Therapeutics to Speak at the JMP Securities Life Sciences Conference

PR Newswire June 18, 2015

Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave® Ignite Study at the Annual Meeting of the American Diabetes Association

PR Newswire June 5, 2015

Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® Patents

PR Newswire June 5, 2015

Zosano Pharma Appoints Joseph P. Hagan to Board of Directors

GlobeNewswire May 27, 2015

Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave Collaboration with Takeda Pharmaceuticals

PR Newswire May 12, 2015

Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of the Cardiovascular Outcomes Study (Light Study) of the Obesity Drug Contrave® (naltrexone HCl and bupropion HCl)

PR Newswire May 12, 2015

OREXIGEN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX

GlobeNewswire May 8, 2015

Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch Health Care Conference

PR Newswire May 8, 2015

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015

Business Wire May 8, 2015

Orexigen Therapeutics Reports Financial and Business Results for the First Quarter Ended March 31, 2015

PR Newswire May 8, 2015

OREX Shareholder Alert: Law Offices of Howard G. Smith Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc.

Business Wire May 5, 2015

Orexigen Therapeutics to Host First Quarter 2015 Financial Results Conference Call

PR Newswire May 5, 2015

OREXIGEN SHAREHOLDERS: Shareholder Rights Law Firm Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit against Orexigen Therapeutics; Investors Encouraged to Contact Firm

Business Wire April 29, 2015

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015

Business Wire April 29, 2015

Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc.

Business Wire April 29, 2015